tbuckley/cabot-search huggingface dataset:
Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation
Authors: M. Teresa de la Morena, David Leonard, Troy R. Torgerson, Otavio Cabral-Marques, Mary Slatter, Asghar Aghamohammadi, Sharat Chandra, Luis Murguia-Favela, Francisco A. Bonilla, Maria Kanariou, Rongras Damrongwatanasuk, Caroline Y. Kuo, Christopher C. Dvorak, Isabelle Meyts, Karin Chen, Lisa Kobrynski, Neena Kapoor, Darko Richter, Daniela DiGiovanni, Fatima Dhalla, Evangelia Farmaki, Carsten Speckmann, Teresa Español, Anna Shcherbina, Imelda Celine Hanson, Jiri Litzman, John M. Routes, Melanie Wong, Ramsay Fuleihan, Suranjith L. Seneviratne, Trudy N. Small, Ales Janda, Liliana Bezrodnik, Reinhard Seger, Andrea Gomez Raccio, J. David M. Edgar, Janet Chou, Jordan K. Abbott, Joris van Montfrans, Luis Ignacio González-Granado, Nancy Bunin, Necil Kutukculer, Paul Gray, Gisela Seminario, Srdjan Pasic, Victor Aquino, Christian Wysocki, Hassan Abolhassani, Morna Dorsey, Charlotte Cunningham-Rundles, Alan P. Knutsen, John Sleasman, Beatriz Tavares Costa Carvalho, Antonio Condino-Neto, Eyal Grunebaum, Helen Chapel, Hans D. Ochs, Alexandra Filipovich, Mort Cowan, Andrew Gennery, Andrew Cant, Luigi D. Notarangelo, Chaim M. Roifman
Journal: Journal of Allergy and Clinical Immunology (2016)
Cam Deformity and Acetabular Dysplasia as Risk Factors for Hip Osteoarthritis
Authors: Fatemeh Saberi Hosnijeh, Maria E. Zuiderwijk, Mathijs Versteeg, Hieronymus T. W. Smeele, Albert Hofman, André G. Uitterlinden, Rintje Agricola, Edwin H. G. Oei, Jan H. Waarsing, Sita M. Bierma‐Zeinstra, Joyce B. J. van Meurs
Journal: Arthritis & Rheumatology (2016)

Cam deformity and acetabular dysplasia have been recognized as relevant risk factors for hip osteoarthritis (OA) in a few prospective studies with limited sample sizes. To date, however, no evidence is available from prospective studies regarding whether the magnitude of these associations differs according to sex, body mass index (BMI), and age.Participants in the Rotterdam Study cohort including men and women ages 55 years or older without OA at baseline (n = 4,438) and a mean follow-up of 9.2 years were included in the study. Incident radiographic OA was defined as a Kellgren/Lawrence grade of ≥2 or a total hip replacement at follow-up. Alpha and center-edge angles were measured to determine the presence of cam deformity and acetabular dysplasia/pincer deformity, respectively. Odds ratios (ORs) were calculated to assess the associations between both deformities and the development of OA.Subjects with cam deformity (OR 2.11, 95% confidence interval [95% CI] 1.55-2.87) and those with acetabular dysplasia (OR 2.19, 95% CI 1.50-3.21) had a 2-fold increased risk of developing OA compared with subjects without deformity, while pincer deformity did not increase the risk of OA. Stratification analyses showed that the associations of cam deformity and acetabular dysplasia with OA were driven by younger individuals, whereas BMI did not influence the associations. Female sex appears to modify the risk of hip OA related to acetabular dysplasia.Individuals with cam deformity and those with acetabular dysplasia are predisposed to OA; these associations were independent of other well-known risk factors. Interestingly, both deformities predisposed to OA only in relatively young individuals. Therefore, early identification of these conditions is important.
Efficacy of galantamine in probable vascular dementia: an effective option for managing behavioural problems
Authors: O'Brien J, Erkinjuntti T, Reisberg B, Roman G, Pantoni L, Bowler Jv, Ballard C, DeCarli C, Gorelick Pb, Rockwood K, Burns, As, Gauthier S, DeKosky St, Sawada T
Journal: The Lancet Neurology (2002)
The Effect of In Vivo T-Cell Depletion with Alemtuzumab on Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia.
Authors: Julio Delgado, Srinivas Pillai, Reuben Benjamin, Dolores Caballero, Rodrigo Martino, Richard Lovell, Kirsty Thomson, Jose A. Perez-Simon, Anna Sureda, Panos Kottaridis, Jesus San Miguel, Karl Peggs, Jorge Sierra, Donald Milligan, Stephen Mackinnon
Journal: Blood (2007)
Long-term Adjuvant Tamoxifen Therapy and Decreases in Contralateral Breast Cancer
Authors: Balkees Abderrahman, V. Craig Jordan
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid
Authors: T. Hashimoto, A. Ohzono, K. Teye, S. Numata, S. Hiroyasu, D. Tsuruta, T. Hachiya, K. Kuroda, M. Hashiguchi, T. Kawakami, N. Ishii
Journal: British Journal of Dermatology (2016)

IgE autoantibodies are considered to be involved in the pathogenesis of bullous pemphigoid (BP), particularly inflammatory and erythematous phenotypes. To develop reliable enzyme‐linked immunosorbent assays (ELISAs) for the detection of IgE autoantibodies to both BP180 and BP230 in BP sera, and to compare the ELISA results with clinical features. We used commercially available IgG ELISAs to develop IgE ELISAs for both BP180 and BP230. To determine the influence of excess amounts of IgG autoantibodies, all normal and BP sera were tested before and after IgG adsorption. The results of the IgE ELISAs were statistically compared with various ELISAs and various clinical parameters, including our own severity scores and BP phenotypes. IgG adsorption generally showed no changes in sensitivity and specificity for IgE ELISAs, although slight cross‐reactivity of anti‐IgE secondary antibody to IgG and interference of excess amounts of IgG autoantibodies to IgE reactivity were suggested. IgE autoantibodies to BP180 were found in 21 of 36 BP sera and IgE autoantibodies to BP230 were found in 18 of 36 BP sera. The results of IgG and IgE ELISAs for both BP180 and BP230 were well correlated. IgG and IgE anti‐BP180 antibodies correlated with disease activity but IgG and IgE anti‐BP230 autoantibodies did not. IgE anti‐BP230 autoantibodies correlated with nodular phenotype but not erythematous phenotype. The results of this study indicated that IgE autoantibodies to both BP180 and BP230 are frequently detected in BP sera. IgE anti‐BP180 autoantibodies seemed to be pathogenic, while an association between IgE autoantibodies and inflammatory BP phenotype was not indicated.
LCIS and tamoxifen use: A single institution review
Authors: L. J. Kirstein, Y. Martei, C. Roche, B. L. Smith, M. C. Specht, M. A. Gadd, B. Drohan, C. Lawrence, J. Michaelson, K. S. Hughes
Journal: Journal of Clinical Oncology (2007)

1527 Background: Results of the NSABP-P1 trial were published in 1998 showing a 50% reduction in breast cancer in the high- risk population with the use of tamoxifen. The use of tamoxifen is individualized, and depends on both patient and physician factors. We looked at the recommendations for and the use of tamoxifen in women with LCIS. Methods: A retrospective chart review at a single institution was performed from March 27, 1980 through September 19, 2005 for patients diagnosed with LCIS. Pathology and operative reports, as well as patient notes were reviewed for discussions about tamoxifen. Data was collected on whether a discussion took place, whether tamoxifen was or was not advised, whether the patient declined to take tamoxifen, whether they took it in the past or were currently on tamoxifen. We also examined the rate of DCIS and invasive cancer in this population. Results: There were 321 patients diagnosed with LCIS. Of those patients 193 were diagnosed after the publication of the P1 trial. Of these 193 patients we identified 104(54%) patients whose charts contained notes indicating a discussion about tamoxifen. The results of the discussion about tamoxifen are as follows: 21(20%) patients were currently taking tamoxifen, 16(15%) had taken it in the past, 37(36%) patients declined to take tamoxifen, and 17(16%) had not made a decision about taking tamoxifen. There were 13(13%) patients for whom tamoxifen was advised against. In the entire cohort of 321 patients, 15% went on to develop DCIS or invasive cancer in the first 12 years of follow up. We did not look at cancer rate Vs tamoxifen use due to the small numbers with available information. Conclusions: While the P1 trial recommends tamoxifen for breast cancer prevention in high-risk patients, in our experience, almost half of the patients did not have a documented discussion about the medication, and the majority of those who did decided not to take tamoxifen. This will likely have a large impact on the rate of DCIS and invasive breast cancer in this group. No significant financial relationships to disclose.
Thiotepa, Fludarabine and Melphalan, a Reduced-Dose Regimen for Allogeneic Haematopoietic Stem Cell Transplantation in Multiple Myeloma
Authors: Ignazio Majolino, Alessandro Severino, Rosanna Scime, Carla Ruscio, Stefania Tringali, Mariarosaria Sajeva, Marcela Gabriel Arana, Caterina Tassone, Luisa Pescador, Fortunato Blandino, Alessandra . Santoro
Journal: Blood (2002)
Injuries among weightlifters and powerlifters: a systematic review
Authors: Ulrika Aasa, Ivar Svartholm, Fredrik Andersson, Lars Berglund
Journal: British Journal of Sports Medicine (2016)

Olympic weightlifting and powerlifting are two sports that expose the body to great forces. Injury characteristics have not been systematically reviewed for these two growing sports.The purpose of this study was to systematically review the literature regarding various definitions of injuries used, injury localisation, the prevalence and incidence of injuries and the associated risk factors for injuries in weightlifting and powerlifting.Systematic review.Five databases, PubMed, MEDLINE, SPORTDiscus, Scopus and Web of Science, were searched between 9 March and 6 April 2015.Studies assessing injury incidence and prevalence in Olympic weightlifting and powerlifting were included. The Quality assessment tool for observational cohort and cross-sectional studies was used to assess methodological quality.9 studies were included in the review. Injury was defined fairly consistently across studies. Most studies were of low methodological quality. The spine, shoulder and the knee were the most common injury localisations in both sports. The injury incidence in weightlifting was 2.4-3.3 injuries/1000 hours of training and 1.0-4.4 injuries/1000 hours of training in powerlifting. Only one retrospective study had analysed possible risk factors.The risk of injury in both sports were similar to other non-contact sports also requiring strength/power, but low compared to contact sports. The severity of injuries differed in the included studies. Since little has been studied regarding possible risk factors to injuries, further research is therefore warranted to explain why athletes get injured and how to prevent injuries.PROSPERO CRD42015014805.
A risk estimation with tumor size, serosal invasion and MIB-1 labeling index for gastrointestinal stromal tumor (GIST) of the stomach
Authors: H. Cho, A. Tsuburaya, O. Kobayashi, M. Sairenji, H. Motohashi
Journal: Journal of Clinical Oncology (2004)

9025 Background: The recently proposed risk estimation (RE) for GIST patients with tumor size and mitotic count has shown to be associated with tumor aggressiveness (Proc ASCO 22: 818, 2003), however, the prediction of recurrence using the risk estimation has not been accurate. The aim of this study is to evaluate clinicopathological factors of GIST of the stomach and develop a new risk critera. Methods:A clinical and pathological analysis of 41 gastric GIST patients in our single institution was performed. All of the patients underwent surgical resection and two patients presented with synchronous metastasis. Median follow-up time was 42 months. Results:Tumor size (p<0.01), serosal invasion (p<0.01), and MIB-1 labeling index (p<0.01) were significantly associated with recurrence. Mitotic count and KIT mutational status were not associated with recurrence. Of the group with tumor size>10 cm and/or positive serosal invasion and/or MIB-1 labeling index>10%, 10 patients (59%) developed recurrence. The sensitivity and the specificity for recurrence of this group was 100% and 77% for each, in contrast, those by RE was 90% and 48% for each. 5-year survival for the above mentioned group was 54%, which was significantly lower than that of the other group (p<0.001). The high risk group by RE was not predictive for survival compared with the other group (p=0.16). Conclusions: Because of the low specificity for recurrence, RE is not satisfactory in view of adjuvant option by imatinib after radical tumor resection. Our risk estimation with tumor size, serosal invasion and MIB-1 labeling index was more useful for prediction of both recurrence and survival of gastric GIST than present risk estimation. No significant financial relationships to disclose.
Avoiding Open-Heart Surgery
Authors: Rebecca Voelker
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PDL-1 and PDL1 expressions in clear cell renal cell carcinoma (ccRCC) of metastatic patients with sunitinib first-line treatment.
Authors: Angélique Brunot, Jean-Christophe Bernhard, Mokrane Yacoub, Julien Edeline, Gregory Verhoest, Karim Bensalah, Frantz Dupuis, Brigitte Laguerre, Pierre Kerbrat, Alain Ravaud, Pascale Bellaud, Roselyne Viel, Florence Jouan, Nathalie Rioux-Leclercq, Solene-Florence Kammerer-Jacquet
Journal: Journal of Clinical Oncology (2015)

e14002 Background: Anti vascular growth epithelial factor (VEGF) therapies are currently used in first line of metastatic ccRCC, but some patients are inherently resistant to these treatments. Immunotherapy based on disruption of immune checkpoints, such as Programmed Death Ligand 1 (PD-L1) and Programmed Death 1 (PD-1), has been showed promising results. Interaction between PD-L1 and PD-1 down-regulates antitumor activity and could be involved in resistance to anti-VEGF therapies Methods: In this study, we assessed PD-L1 and PD-1 expressions by immunohistochemistry in primary ccRCC of metastatic patients with sunitinib first-line treatment. From 2 centers, 92 patients were restrospectively included and clinical data were collected with a median follow up of 22 months after sunitinib introduction. PD-L1 immunostaining was evaluated on the highest Fuhrman grade areas (n = 92) and PD-1 on the most inflammatory territory when the corresponding block was available (n = 47). PD-L1 and PD-1 were considered overexpressed when moderate to intense membranous tumor cells staining and moderate to marked tumor infiltrating lymphocytes staining were observed, respectively. Results: Patients with PD-L1 overexpression (n = 65/92, 71%) had significantly shorter progression free survival (PFS) compared to other patients (median 10 vs 19 months, p = 0.01). There was also a trend toward a worse overall survival (OS) (median 18 vs 26 months, p = 0.24). In the subgroup with PD-1 results available, patients with both PD-L1 and PD-1 overexpressions (n = 17/47) had an even shorter PFS (median 9 vs 19 months, p = 0.001), and a comparable OS (median 18 vs 32 months, p = 0.2). Conclusions: This is the first study to assess both PD-L1 and PD-1 expressions in metastatic patients with sunitinib first-line treatment. Patients with PD-L1 as well as both PD-L1 and PD-1 overexpressions were associated with worse clinical outcomes, and should be individualized as having a peculiar immune phenotype. These patients experienced poor prognosis when treated by sunitinib and may benefit more from anti-PD-1 or anti-PD-L1 immunotherapies.
Expression of RUNX1 and RUNX1T1 Correlates with Cytogenetic Subgroups in Pediatric AML: A Report From the Children's Oncology Group
Authors: Matthew A. Kutny, Todd A. Alonzo, Robert B. Gerbing, Janet Franklin, Susana C. Raimondi, Betsy A. Hirsch, Alan S. Gamis, Soheil Meshinchi
Journal: Blood (2012)
LAT Down-Regulation in T Lymphocytes from B-Cell Chronic Lymphocytic Leukemia: A Possible Mechanism for T Cell Incompetence.
Authors: Maristella Tassi, Donatella Raspadori, Mariapia Lenoci, Francesco Forconi, Maria Antonietta Dell’Aversano, Ida Chitarrelli, Francesco Lauria
Journal: Blood (2006)
Induction of Fetal Hemoglobin by Transcriptional Co-Activators MTF-1 and TSPYL1
Authors: Kenneth R Peterson, Flavia C Costa, Halyna Fedosyuk, Renee Neades, Johana Bravo de los Rios, Andrea Fonteles, Lesya Zelenchuk, Prarthana Dalal, Gabriella Maniscalco
Journal: Blood (2011)
P0397 : Nrf2 mutations are an early and frequent event in the development of rat hepatocellular carcinoma
Authors: A. Columbano, S. Giordano, A. Perra, M.A. Kowalik, G.M. Ledda-Columbano, A. Petrelli, S. Menegon, L. Quagliata, L. Terraciano, P. Zavattari
Journal: Journal of Hepatology (2015)
Effect of lymphoid tissue inducer cells on lymphatic tumor cell invasion via activation of the RANKL/RANK axis within triple-negative breast cancers.
Authors: Sheeba Irshad, Katherine Lawler, Fabian Flores-Borja, James Monypenny, Rachel Evans, Anita Grigoriadis, Gilbert Fruhwirth, Anthony Cheung, Paul Barber, Paul Anthony Ellis, Andrew Nicholas James Tutt, Tony Ng
Journal: Journal of Clinical Oncology (2014)

11082 Background: Inflammation and infiltration of the tumor tissue by host immune cells have been shown to promote tumor cell invasion and metastasis. The exact molecular mechanisms mediating tumor cell entry and persistence within the lymphatics remains unclear. We previously reported the novel identification of retinoic acid receptor related orphan receptor (ROR)gt+lymphoid tissue inducer cells (LTIs) within breast cancer tumor microenvironments. The presence of these cells was shown to be associated with a high expression of a lymphoid chemokine gene signature; correlating also with an increased lymphatic vessel density and tumor invasion into lymphatic vessels. Here we report on the mechanistic relationship between LTi cells and tumor cell invasion. Methods: Both in vitro and in vivo experiments were carried out to further investigate the correlations observed within our human dataset. Results: We report the temporal sequence of LTi cell recruitment into first the primary tumors and then into the draining lymph nodes during tumour progression within a triple negative breast cancer (4T1.2) mouse model. These changes were closely associated with changes in the serum levels of associated lymphoid chemokines (CCL21 and CXCL13) and RANKL (a key regulator of LTi cell function). The administration of blocking antibodies for CCL21, CXCL13 or RANKL in vivo demonstrated i) LTi recruitment into tumors was dependent primarily on CCL21; ii) migration of LTi cells from the tumors to the draining lymph nodes was likely to be dependent on CXCL13; and iii) RANKL blocking was associated with significantly delayed onset of metastasis within the draining lymph node. Our in vitro studies demonstrate that an increase in stromal CXCL13 concentration within the tumor microenvironment following LTi recruitment promotes an EMT phenotype in the 4T1.2 cancer cell line, possibly via activation of the RANKL/RANK axis promoting an increase in tumor cell motility. Conclusions: We propose a pivotal role for LTi cells, through stromal cell interactions in the tumor microenvironment, in facilitating lymphatic invasion of tumor cells through modulation of the local lymphoid chemokine profile.
Redox Regulation of Mitochondrial ATP Synthase
Authors: Sheng-Bing Wang, D. Brian Foster, Jasma Rucker, Brian O'Rourke, David A. Kass, Jennifer E. Van Eyk
Journal: Circulation Research (2011)

Rationale: Cardiac resynchronization therapy (CRT) is an effective clinical treatment for heart failure patients with conduction delay, impaired contraction, and energetics. Our recent studies have revealed that mitochondrial posttranslational modifications (PTM) may contribute to its benefits, motivating the present study of the oxidative regulation of mitochondrial ATP synthase. Objectives: We tested whether CRT alteration of ATP synthase function is linked to cysteine (Cys) oxidative PTM (Ox-PTM) of specific ATP synthase subunits. Methods and Results: Canine left ventricular myocardium was collected under conditions to preserve Ox-PTM from control, dyssynchronous heart failure (DHF), or hearts that had undergone CRT. In-gel ATPase activity showed that CRT increased ATPase activity by ≈2-fold ( P &lt;0.05) over DHF, approaching control levels, and this effect was recapitulated with a reducing agent. ATP synthase function and 3 Ox-PTM: disulfide bond, S-glutathionylation and S-nitrosation were assessed. ATP synthase from DHF hearts contained 2 novel disulfide bonds, between ATP synthase α subunits themselves and between α and γ subunits, both of which were decreased in CRT hearts (4.38±0.13- and 4.23±0.36-fold, respectively, P &lt;0.01). S-glutathionylation of ATP synthase α subunit occurred in DHF hearts and was decreased by CRT (1.56±0.16-fold, P &lt;0.04). In contrast, S-nitrosation of ATP synthase α subunit in DHF hearts was lower than in CRT hearts (1.53±0.19-fold, P &lt;0.05). All modifications occurred at ATP synthase α subunit Cys294 and Cys to Ser mutation indicated that this residue is critical for ATP synthase function. Conclusions: A selective Cys in ATP synthase α subunit is targeted by multiple Ox-PTM suggesting that this Cys residue may act as a redox sensor modulating ATP synthase function.